Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) EBITDA Margin (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBITDA Margin for 15 consecutive years, with 3.34% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 1204.0% to 3.34% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.25%, a 581.0% decrease, with the full-year FY2024 number at 3.87%, down 296.0% from a year prior.
  • EBITDA Margin was 3.34% for Q3 2025 at Usana Health Sciences, down from 5.87% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 10.54% in Q4 2023 to a low of 261362.5% in Q3 2021.
  • A 5-year average of 14472.11% and a median of 5.11% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -26137329bps in 2021, then skyrocketed 26136646bps in 2022.
  • Usana Health Sciences' EBITDA Margin stood at 9.77% in 2021, then fell by -10bps to 8.78% in 2022, then rose by 20bps to 10.54% in 2023, then crashed by -120bps to 2.11% in 2024, then plummeted by -58bps to 3.34% in 2025.
  • Per Business Quant, the three most recent readings for USNA's EBITDA Margin are 3.34% (Q3 2025), 5.87% (Q2 2025), and 3.69% (Q1 2025).